Radiopharmaceutical Theranostics Market6

MANISH
MANISH 4/12/2023 1:48:04 PM

Radiopharmaceutical Theranostics Market Global
Players, Revenue and Growth, Research and Forecast to 2028

Radiopharmaceutical Theranostics Market” study by “The Insight Partners” provides details about the market dynamics affecting the market, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favorable competitive landscape and trends prevailing over the years.

For Sample Report Click: - https://www.theinsightpartners.com/sample/TIPRE00024328/

Companies Mentioned: Bayer AG,GE HealthCare Technologies Inc,Curium,Lantheus Medical Imaging, Inc. ,Telix Pharmaceuticals Ltd.,Cardinal Health Inc,Advanced Accelerator Applications S.A.,Jubilant Radiopharma,Theragnostics,NuView Life Sciences.

The global radiopharmaceutical theranostics market, based on source, is bifurcated into nuclear reactors and cyclotrons. The cyclotrons segment held the largest share of the market, and the same segment is expected to register a faster CAGR in the coming years. Cyclotrons are best suited for producing proton-rich radioisotopes such as Fluorine-18 (18F). Commercially available cyclotron-produced medical radioisotope involves Carbon-11, Nitrogen-13, Oxygen-15, Fluorine-18 (18F), Copper-64, Gallium-67, Iodine-123, and Thallium-201. According to the International Atomic Energy Agency (IAEA) 2023 report, the most frequent radioisotope produced through cyclotrons are those with short half-lives, particularly fluorine-18, carbon-11, oxygen-15, and nitrogen-13, intended for imaging techniques such as positron emission tomography (PET). Cyclotrons account for almost 95% of the production of radiopharmaceuticals used in PET. Additionally, the demand for cyclotrons is increasing as radionuclides are majorly used in research, diagnosis, and treatment of a range of life-threatening diseases such as cancer, Parkinson's, and Alzheimer's. Further, medical imaging techniques such as PET and SPECT depend on cyclotron-produced radioisotopes. Cyclotrons segment fall under safety and security measures as it is not subjected to any harmful reactors on exposure.

The Radiopharmaceutical Theranostics Market is segmented on the basis of type, application, end user, and geography. By geography, the market is broadly segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The report offers insights and in-depth analysis of the market, emphasizing on parameters such as market trends, technological advancements, and market dynamics, along with the competitive landscape analysis of the world's leading market players.

Key Elements that the report acknowledges:

Market size and growth rate during forecast period.

Key factors driving the “Radiopharmaceutical Theranostics market” market.

Key market trends cracking up the growth of the “Radiopharmaceutical Theranostics market” market.

Challenges to market growth.

Key vendors of “Radiopharmaceutical Theranostics market” market.

Detailed SWOT analysis.

Opportunities and threats faces by the existing vendors in Global “Radiopharmaceutical Theranostics” market.

Trending factors influencing the market in the geographical regions.

Strategic initiatives focusing the leading vendors.

PEST analysis of the market in the five major regions.

About The Insight Partners:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876

                                                          

                                                                                 


MANISH
Written by

MANISH

Post a comment